Skip to Main Content
Page banner

COVID-19 - Influenza Multiplexed Test (Celltrion)

Multiplexed COVID-19 and Influenza all in one test. 

Name: Celltrion DiaTrust COVID-19/Influenza Ag Duo Rapid Test

Background: Celltrion is a pharmaceutical company with a strong relationship with British and European pharmaceutical and healthcare bodies and expertise in this area. 

The FDA has given Emergency Use Authorisation to Celltrion's diagnostic kits approximately 1 week ago.

Summary:

- Provides dual diagnosis of SARS-CoV-2 and Influenza A/B infection
- Fast results within 15 minutes, No additional instrument required
- Simple test procedure using a direct nasal swab
- Accurate results with high sensitivity and specificity
- On-site diagnosis with lab-quality results at the point of care
 
 

 

Have you validated this method, if so, how and what were the results of the validation?

Available on request

Is the method already deployed in a UK hospital or clinical setting?

No

Where is the kit manufactured?

South Korea

Possibility for direct manufacturing onshoring / UK license agreement too. 

What is the turn around time (sample-to-result) for this method?

15 minutes

How will your solution communicate directly with the Laboratory Information Management System (LIMS)?

TBD

How quickly could this be deployed and what are the dependencies?

Available to partner and supply now 

Celltrion already supplying globally including partnership with FDA for emergency use. 

What is the likely production volume?

Unlimited 

What are the risks and barriers to using this at scale?

None - already being produced at scale

Who are you already partnering with on this?

We are partnering with most major countries globally. 

edited on Nov 3, 2020 by Dr Dan Casey, Pharmaceutical Physician
You will need to login to post a comment
No comments yet, be the first to post one!
Share